Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) EBT (2016 - 2025)

ImmunityBio (IBRX) has disclosed EBT for 12 consecutive years, with -$62.1 million as the latest value for Q4 2025.

  • On a quarterly basis, EBT fell 4.92% to -$62.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$351.6 million, a 15.0% increase, with the full-year FY2025 number at -$351.6 million, up 15.0% from a year prior.
  • EBT was -$62.1 million for Q4 2025 at ImmunityBio, up from -$67.3 million in the prior quarter.
  • In the past five years, EBT ranged from a high of -$59.2 million in Q4 2024 to a low of -$233.5 million in Q4 2023.
  • A 5-year average of -$105.8 million and a median of -$95.2 million in 2022 define the central range for EBT.
  • Peak YoY movement for EBT: crashed 344.96% in 2021, then surged 74.65% in 2024.
  • ImmunityBio's EBT stood at -$91.6 million in 2021, then fell by 18.28% to -$108.3 million in 2022, then plummeted by 115.58% to -$233.5 million in 2023, then soared by 74.65% to -$59.2 million in 2024, then decreased by 4.92% to -$62.1 million in 2025.
  • Per Business Quant, the three most recent readings for IBRX's EBT are -$62.1 million (Q4 2025), -$67.3 million (Q3 2025), and -$92.3 million (Q2 2025).